拉蒂戈生物治疗
LTGO
14.00
-0.76
-5.15%
拉蒂戈生物治疗
US · LTGO
#3230 按市值排名
上市于 2026
14.00
-0.76
-5.15%
实时 - 追踪5344个代码 - 心跳于21秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量增加了10家。
- 机构持股总比例上升了65.5个百分点。
机构持股
- 机构持股比例
- 65.54% +65.54pp
- 机构数量
- 10 +10
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund59.50%
Individual/Insider6.52%
Hedge Fund4.75%
Public Company1.01%
Private Company0.17%
Mutual Fund0.10%
Other27.95%
主要股东 截至 2026-08-10
Westlake Village BioPartners
19.91% · 13.20M 股
Foresite Capital Management, LLC
13.85% · 9.18M 股
5AM Venture Management, LLC
11.05% · 7.33M 股
RA Capital Management, L.P.
7.99% · 5.30M 股
Deep Track Capital, LP
6.71% · 4.45M 股
Leonard Blavatnik
4.80% · 3.19M 股
Blue Owl Credit Private Fund Advisors LLC
4.75% · 3.15M 股
Sanofi
1.01% · 672.79K 股
Neil Singla
0.80% · 532.80K 股
Timothy Walbert
0.50% · 329.82K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪20份申报 · 6次买入 · 0次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Westlake Village BioPartners | -- | 19.91% |
| Foresite Capital Management, LLC | -- | 13.85% |
| 5AM Venture Management, LLC | -- | 11.05% |
| Timothy Walbert | Independent Chairperson | 0.50% |
| Sara Bonstein | Independent Director | 0.16% |
| James Tananbaum | Independent Director | -- |
| Sanofi | -- | -- |
| Andrew Schwab | -- | -- |
| Todd Smith | Independent Director | -- |
| Nima Farzan | Chief Executive Officer | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-09 | Sanofi | -- | Derivative Exercise and Retained | +672,778 | -- |
| 2026-08-09 | 5AM Venture Management, LLC | -- | Derivative Exercise and Retained | +7,325,962 | -- |
| 2026-08-09 | Foresite Capital Management, LLC | -- | Open Market Acquisition | +140,000 | $18.00 |
| 2026-08-09 | Foresite Capital Management, LLC | -- | Derivative Exercise and Retained | +9,041,328 | -- |
| 2026-08-09 | Westlake Village BioPartners | -- | Derivative Exercise and Retained | +12,695,305 | -- |
| 2026-08-05 | James Tananbaum | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Sanofi | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Andrew Schwab | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Timothy Walbert | Independent Chairperson | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Todd Smith | Independent Director | Other Derivative Acquisition | +105,542 | $18.00 |
| 2026-08-05 | Nima Farzan | Chief Executive Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Sara Bonstein | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Westlake Village BioPartners | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-05 | Neha Krishnamohan | Chief Business Officer & CFO | Initial Statement of Beneficial | 0 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
拉蒂戈生物治疗 讨论区 0 条评论